US Patent Issued to THE UNIVERSITY OF MONTANA on Dec. 16 for "Vaccine adjuvants based on TLR receptor ligands" (Montana Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,496,340, issued on Dec. 16, was assigned to THE UNIVERSITY OF MONTANA (Missoula, Mont.).

"Vaccine adjuvants based on TLR receptor ligands" was invented by Helene Bazin-Lee (Stevensville, Mont.), David Burkhart (Missoula, Mont.) and Jay Evans (Corvallis, Mont.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmnune disorders."

The patent was filed on May 22, 2020, under Application No. 17/613,414.

*For further information, including images,...